Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kindstar Globalgene Technology has a current ratio of 2.81. It generally indicates good short-term financial strength.
The historical rank and industry rank for Kindstar Globalgene Technology's Current Ratio or its related term are showing as below:
HKSE:09960'
s Current Ratio Range Over the Past 10 Years
Min: 0.27 Med: 2.72 Max: 5.68
Current: 2.81
During the past 8 years, Kindstar Globalgene Technology's highest Current Ratio was 5.68. The lowest was 0.27. And the median was 2.72.
HKSE:09960's Current Ratio is ranked better than 62.62% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.17
vs HKSE:09960: 2.81
Kindstar Globalgene Technology (HKSE:09960) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Kindstar Globalgene Technology Current Ratio Related Terms
Kindstar Globalgene Technology Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kindstar Globalgene Technology Current Ratio Chart
HKSE:09960 vs TMO, DHR, NTRA: Current Ratio Comparison
For the Diagnostics & Research subindustry, Kindstar Globalgene Technology's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kindstar Globalgene Technology Current Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Kindstar Globalgene Technology's Current Ratio distribution charts can be found below:
* The bar in red indicates where Kindstar Globalgene Technology's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kindstar Globalgene Technology (HKSE:09960) has a Current Ratio of 2.81 as of Dec. 2025. This is near median its historical median of 2.72. Over the past decade, Kindstar Globalgene Technology's Current Ratio has ranged from 0.27 to 5.68. According to the industry distribution chart, Kindstar Globalgene Technology ranks #80 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 37.4%.
Is Kindstar Globalgene Technology's Current Ratio too high?
Kindstar Globalgene Technology's current Current Ratio of 2.81 is near median its 10-year median of 2.72. Over the past 10 years, this metric has ranged from a low of 0.27 to a high of 5.68. The Medical Diagnostics & Research industry median Current Ratio is 2.17. Kindstar Globalgene Technology's value of 2.81 is 29.5% above this industry median. Based on the distribution chart, Kindstar Globalgene Technology ranks #80 out of 214 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Kindstar Globalgene Technology has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Kindstar Globalgene Technology's Current Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Kindstar Globalgene Technology ranks #80 out of 214 companies for Current Ratio. This puts Kindstar Globalgene Technology in the upper half of its industry. The industry median Current Ratio is 2.17. Kindstar Globalgene Technology's value of 2.81 is 29.5% above this benchmark. Historically, Kindstar Globalgene Technology's own Current Ratio has ranged from 0.27 to 5.68 over the past decade. While the company's 10-year median is 2.72 vs. the industry median of 2.17, Kindstar Globalgene Technology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Diagnostics & Research company?
The median Current Ratio among Medical Diagnostics & Research companies is 2.17, based on 214 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kindstar Globalgene Technology's current Current Ratio of 2.81 is 29.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Current Ratio is 2.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kindstar Globalgene Technology's current Current Ratio is 2.81, which is near median its own 10-year median of 2.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kindstar Globalgene Technology stock overvalued right now?
Based on GuruFocus' analysis, Kindstar Globalgene Technology (HKSE:09960) is currently considered Fairly Valued. The stock's GF Value™ is HK$1.06, compared to a current price of HK$1.00 — trading 5.7% below its estimated fair value. The current Current Ratio is 2.81, which is near median its 10-year median of 2.72 and 29.5% above the Medical Diagnostics & Research industry median of 2.17. Kindstar Globalgene Technology's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Kindstar Globalgene Technology (HKSE:09960), the current Current Ratio is 2.81 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kindstar Globalgene Technology (HKSE:09960) Overvalued in 2026?
Based on GuruFocus' analysis, Kindstar Globalgene Technology stock appears to be undervalued.
The current stock price of HK$1.00 is trading 5.7% below its estimated GF Value™ of HK$1.06.
GuruFocus considers Kindstar Globalgene Technology to be Fairly Valued.
Key valuation signals for HKSE:09960:
Current Ratio: 2.81 (near median its 10-year median of 2.72)
GF Value™: HK$1.06 vs. price of HK$1.00 (5.7% below fair value)
Industry Position: 29.5% above the Medical Diagnostics & Research median (#80 of 214)
No single metric tells the full story. See the HKSE:09960 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kindstar Globalgene Technology Inc is engaged in the provision of clinical testing services in China. It operates in nine segments: Hematology testing segment includes testing services related to blood diseases; Genetic diseases and rare diseases segment includes testing services for rare diseases; Infectious diseases segment includes testing services from the infection department; Oncology segment includes testing related to oncology diseases; Neurology segment includes testing services related to neurological diseases undertaken by the Group; Maternity-related diseases segment includes testing services related to maternity; Routine testing segment conducts routine tests for the doctors daily diagnoses; CROs & R&D project segment includes research & develop services; & others segment.
69GF Score
Get the complete analysis for HKSE:09960
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:09960 has been successfully added to your 
